| Literature DB >> 27406629 |
Giovanna Mariscotti1, Paolo Belli2, Daniela Bernardi3, Beniamino Brancato4, Massimo Calabrese5, Luca A Carbonaro6, Beatrice Cavallo-Marincola7, Francesca Caumo8, Paola Clauser9,10, Laura Martinchich11, Stefania Montemezzi12, Pietro Panizza13, Federica Pediconi7, Alberto Tagliafico14, Rubina M Trimboli6, Chiara Zuiani10, Francesco Sardanelli15,16.
Abstract
Women who underwent chest radiation therapy (CRT) during pediatric/young-adult age (typically, lymphoma survivors) have an increased breast cancer risk, in particular for high doses. The cumulative incidence from 40 to 45 years of age is 13-20 %, similar to that of BRCA mutation carriers for whom contrast-enhanced magnetic resonance imaging (MRI) is recommended. However, in women who underwent CRT, MRI sensitivity is lower (63-80 %) and that of mammography higher (67-70 %) than those observed in women with hereditary predisposition, due to a higher incidence of ductal carcinoma in situ with microcalcifications and low neoangiogenesis. A sensitivity close to 95 % can be obtained only using mammography as an adjunct to MRI. Considering the available evidence, women who underwent CRT before 30 receiving a cumulative dose ≥10 Gy should be invited after 25 (or, at least, 8 years after CRT) to attend the following program: 1. interview about individual risk profile and potential of breast imaging; 2. annual MRI using the same protocol recommended for women with hereditary predisposition; 3. annual bilateral two-view full-field digital mammography or digital breast tomosynthesis (DBT) with synthetic 2D reconstructions. Mammography and MRI can be performed at once or alternately every 6 months. In the case of MRI or contrast material contraindications, ultrasound will be performed instead of MRI. Reporting using BI-RADS is recommended. At the age for entering population screening, the individual risk profile will be discussed with the woman about opting for only mammography/DBT screening or for continuing the intensive protocol.Entities:
Keywords: Breast cancer; Lymphoma survivors; MRI; Screening
Mesh:
Substances:
Year: 2016 PMID: 27406629 DOI: 10.1007/s11547-016-0667-9
Source DB: PubMed Journal: Radiol Med ISSN: 0033-8362 Impact factor: 3.469